Arrowhead Pharmaceuticals (ARWR) Income from Non-Controlling Interests (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 10 years of Income from Non-Controlling Interests data on file, last reported at -$4.8 million in Q1 2026.

• Quarterly Income from Non-Controlling Interests fell 87.45% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 547.05% YoY) and the FY2025 annual result came in at $2.1 million, down 43.71% from the prior year.
• Income from Non-Controlling Interests declined to -$4.8 million in Q1 2026, from $146000.0 in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $10.3 million in Q3 2025 to a low of -$4.8 million in Q1 2026.
• A 5-year average of $350214.3 and a median of -$77000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
• The widest YoY moves for Income from Non-Controlling Interests: up 631.69% in 2025, down 1295.37% in 2025.
• Tracing ARWR's Income from Non-Controlling Interests over 5 years: stood at -$486000.0 in 2022, then jumped by 492.8% to $1.9 million in 2023, then plunged by 126.56% to -$507000.0 in 2024, then jumped by 128.8% to $146000.0 in 2025, then tumbled by 3415.07% to -$4.8 million in 2026.
• The last three Income from Non-Controlling Interests figures came in at -$4.8 million (Q1 2026), $146000.0 (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.